<DOC>
	<DOCNO>NCT00418678</DOCNO>
	<brief_summary>This Phase IV , open-label , sequential treatment study patient receive standard chemotherapy non-small cell lung cancer , breast cancer , colorectal cancer . ( See Section 4.2.1 eligible treatment regimen . ) The study take place first 2 cycle chemotherapy . Phase 1 study : Prior first dose chemotherapy , patient instruct complete patient diary , include Visual Analogue Scale ( VAS ) nausea VAS pain . In addition , diary include section list current pain medication ( see Sample Patient Diary Appendix I ) . After instructed , patient complete VAS nausea pain , well list current pain medication . Patients receive chemotherapy Day 1 Cycle 1 combination pre-defined standard serotonin antagonist/corticosteroid regimen . Beginning Day 2 , diary complete 5 consecutive day ( Days 2-6 ) . Each day , patient complete diary entry pertain precede 24 hour . The entry include number time emetic episode , antiemetic rescue medication use , VAS nausea , side effect treatment . On last day diary ( Day 6 ) , entry include daily parameter also include VAS pain . In addition , patient complete diary entry pertain 5-day study period include pain medication use . Patients also complete Functional Living Index - Cancer ( FLIC ) questionnaire ( see Sample Function Living Index - Cancer questionnaire Appendix II ) . Patients either least one vomit episode least one report significant nausea ( VAS &gt; 25 mm ) first 5-day study period eligible second phase study . Phase 2 study : Patients second phase receive second cycle chemotherapy . The antiemetic regimen second cycle serotonin antagonist/corticosteroid regimen receive Cycle 1 , addition Cesamet . For Cycle 2 treatment , patient receive Cesamet 1 mg night chemotherapy administer . On day chemotherapy ( Day 1 Cycle 2 ) , Cesamet 2 mg give 1 3 hour chemotherapy administer , addition serotonin antagonist/corticosteroid regimen receive Cycle 1 . Patients receive additional dose Cesamet 2 mg even Day 1 . Patients receive Cesamet 2 mg BID Days 2-5 . Patients complete 5-day diary FLIC questionnaire Cycle 1 . Beneficial effect Cesamet estimate compare result second cycle result first cycle . Patients evaluate first 2 cycle chemotherapy .</brief_summary>
	<brief_title>A Phase IV Trial Cesametâ„¢ Given With Standard Antiemetic Therapy Chemotherapy-induced Nausea Vomiting</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Antiemetics</mesh_term>
	<mesh_term>Nabilone</mesh_term>
	<criteria>1 . Patients must sign IRBapproved informed consent . 2 . Patients must receive moderately emetogenic chemotherapy first time one follow neoplasms/regimens : Nonsmall cell lung cancer receive paclitaxel carboplatin Breast cancer receive cyclophosphamide doxorubicin Colorectal cancer receive FOLFOX regimen . 3 . Patients must ECOG Performance Status 0 1 ( see Appendix I ) . 4 . Patients must &gt; 18 year age . 5 . Patients must either child bear potential negative serum pregnancy test within 7 day prior registration . Patients consider child bear potential surgically sterile ( undergone hysterectomy , bilateral tubal ligation bilateral oophorectomy ) postmenopausal least 12 month . 6 . Patients childbearing potential must agree use effective contraceptive measure study treatment reasonable time thereafter . 7 . Patients must adequate bone marrow function base requirement specify prescribe guideline chemotherapy regimen . 8 . Patients must adequate renal hepatic function base requirement specify prescribe guideline chemotherapy regimen . 1 . Patients preexist nausea vomit . 2 . Patients potential cause nausea vomiting , include uncontrolled brain metastasis , bowel obstruction , gastrointestinal hemorrhage . 3 . Patients prior adjuvant chemotherapy . 4 . Patients receive concurrent radiotherapy brain upper abdomen . 5 . Patients currently take antiemetic . 6 . Patients history hypersensitivity cannabinoid . 7 . Patients serious uncontrolled intercurrent medical illness , include serious infection . 8 . Patients current previous psychiatric disorder ( include manic depressive illness schizophrenia ) , symptoms disease state may unmask use cannabinoids . Cesamet use caution individual receive psychoactive drug . 9 . Patients hypertension heart disease , since Cesamet elevate supine stand heart rate cause postural hypotension . 10 . Patients history malignancy within last 5 year , could affect diagnosis assessment study drug . 11 . Any patient pregnant lactating . 12 . Any patient unable comply requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2008</verification_date>
</DOC>